Cancer | Subgroupd | Model 1 | Model 2a | ||
---|---|---|---|---|---|
HRb (95% CI) | P | HR (95% CI) | P | ||
NSCLC | |||||
 Stage I | Intermediate | 1.47 (1.36–1.58) | < 0.001 | 1.04 (0.95–1.13) | 0.349 |
Long | 2.05 (1.85–2.25) | < 0.001 | 1.11 (1.01–1.23) | 0.044 | |
 Stage II | Intermediate | 1.20 (1.07–1.33) | 0.001 | 0.97 (0.87–1.09) | 0.699 |
Long | 1.48 (1.28–1.70) | < 0.001 | 1.00 (0.86–1.16) | 0.995 | |
IBC | |||||
 Stage I | Intermediate | 0.91 (0.86–0.96) | 0.001 | 0.92 (0.87–0.97) | 0.003 |
Long | 1.20 (1.08–1.34) | < 0.001 | 1.23 (1.11–1.37) | < 0.001 | |
 Stage II | Intermediate | 0.86 (0.82–0.90) | < 0.001 | 0.93 (0.88–0.97) | 0.002 |
Long | 1.10 (1.01–1.20) | 0.038 | 1.09 (0.99–1.19) | 0.059 | |
DTC | |||||
 Stage I | Intermediate | 0.43 (0.33–0.57) | < 0.001 | 0.70 (0.53–0.93) | 0.012 |
Long | 0.76 (0.49–1.19) | 0.236 | 1.09 (0.70–1.70) | 0.711 | |
 Stage II | Intermediate | 0.74 (0.43–1.29) | 0.295 | 0.73 (0.41–1.31) | 0.300 |
Long | 0.21 (0.03–1.50) | 0.120 | 0.22 (0.03–1.61) | 0.138 | |
Colorectal cancer | |||||
 Stage I | Intermediate | 0.97 (0.88–1.06) | 0.503 | 0.83 (0.75–0.92) | < 0.001 |
Long | 1.60 (1.29–2.00) | < 0.001 | 1.21 (0.97–1.52) | 0.090 | |
 Stage II | Intermediate | 0.71 (0.66–0.76) | < 0.001 | 0.70 (0.65–0.75) | < 0.001 |
Long | 1.32 (1.11–1.57) | 0.001 | 0.87 (0.72–1.04) | 0.120 | |
Cervical cancer | |||||
 Stage I | Intermediate | 1.75 (1.48–2.08) | < 0.001 | 1.08 (0.90–1.30) | 0.421 |
Long | 1.70 (1.28–2.26) | < 0.001 | 0.84 (0.63–1.14) | 0.282 | |
 Stage II | Intermediate | 1.04 (0.85–1.27) | 0.713 | 0.92 (0.74–1.14) | 0.436 |
Long | 1.15 (0.86–1.54) | 0.340 | 1.01 (0.75–1.37) | 0.949 |